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Abstract: BACKGROUND Interstitial lung (ILD) disease and Granulomatous lung disease (GLD) are
rare respiratory disorders that have been associated with inflammatory bowel disease (IBD). Clinical
presentation is polymorphic and aetiology is unclear. METHODS This was an ECCO-CONFER project.
Cases of concomitant ILD or GLD and IBD or drug induced ILD/GLD were collected. The criteria for
diagnosing ILD and GLD were based on definitions from the American Thoracic Society and European
Respiratory Society and on the discretion of reporting clinician. RESULTS We identified 31 patients
with ILD, majority had ulcerative colitis (UC) (n=22). Drug related ILD was found in 64% of patients.
Twenty five patients (80.6%) required hospitalization and 1 required non-invasive ventilation. Causative
drug was stopped in all drug related ILD and 87% of patients received systemic steroids. At follow up 16%
of patients had no respiratory symptoms, 16% had partial improvement, 55% had ongoing symptoms,
no data in 13%. One patient was referred for lung transplantation and 1 death from lung fibrosis was
reported. We also identified 22 GLD patients, most had Crohn’s disease (CD) (n=17). Drug related GLD
was found in 36% of patients. Ten patients (45.4%) required hospitalization. Causative drug was stopped
in all drug related GLD and 81% of patients received systemic steroids. Remission of both conditions
was achieved in almost all patients. CONCLUSIONS ILD and GLD although rare can cause significant
morbidity. In our series over half of cases were drug related and therefore focused pharmacovigilance is
needed to identify and manage these cases.
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Background:  Interstitial lung (ILD) disease and Granulomatous lung disease (GLD) are rare respiratory 
disorders that have been associated with inflammatory bowel disease (IBD). Clinical presentation is 
polymorphic and aetiology is unclear.  
Methods: This was an ECCO-CONFER project. Cases of concomitant GLD or ILD and IBD or drug 
induced ILD/GLD were collected.  The criteria for diagnosing ILD and GLD were based on definitions 
from the American Thoracic society and European Respiratory society and on the discretion of reporting 
clinician.  
Results: We identified 31 patients with ILD, most of them with ulcerative colitis (UC) (n=22). Drug 
related ILD was found in 64% of patients. Twenty five patients (80.6%) required hospitalization and 1 
required non-invasive ventilation. Causative drug was stopped in all drug related ILD and 87% of patients 
received systemic steroids. At follow up 45% of patients had no respiratory symptoms, 22.5% had partial 
improvement and 13% had ongoing symptoms. One patient underwent lung transplantation and 1 death 
from lung fibrosis was reported. We also identified 22 GLD patients with mean age of 46 years (18-86), 
most of them with Crohn’s disease (CD) (n=17). Fourteen patients had non drug related GLD. Ten 
patients (45.4%) required hospitalization but none required invasive ventilation. Causative drug was 
stopped in all drug related GLD and 81% of patients received systemic steroids. Remission of both 
conditions was achieved in almost all patients.  
Conclusions: ILD and GLD although rare can cause significant morbidity. In our series over half of 




Up to 50% of IBD patients experience at least one extra-intestinal manifestation (EIM), such as pyoderma 
gangrenosum, uveitis, episcleritis, polyarthritis or thromboembolic disease1-3. Bronchopulmonary 
manifestations, despite being considered rare with an unknown prevalence, are increasingly recognized. 
4 
The presentation of broncho-pulmonary manifestations in IBD patients is polymorphic, as all 
segments of the respiratory tract can be affected. Generally, pulmonary involvement in IBD may be 
associated with IBD medication or an EIM of the disease itself. 4 
IBD related lung disease can be subclassified into airway diseases, autoimmune disorder, 
interstitial lung disease, granulomatous disease and fistulas (Table 1)5. Particularly, interstitial lung 
disease (ILD)  and granulomatous lung disease (GLD) and are both rare respiratory conditions.  GLD, 
mimicking parenchymal sarcoidosis, may be observed in CD patients. In fact, patients with CD and 
concomitant sarcoidosis have been reported in the literature, suggesting a link between the two diseases, 
which share susceptibility genes4. ILD is a heterogeneous group of disorders characterized by varying 
degrees of fibrosis and inflammation of lung parenchyma. There are estimates of more than 200 known 
causes of ILD leading to symptoms and radiological changes. These diseases can be classified based on 
the definitions from the American Thoracic society and European Respiratory society 5-7.   
Drug related lung disease can present with either interstitial lung disease or granulomatous 
disease. The diagnosis of drug related disease can be based on several criteria8:  
1. A history of drug exposure with correct identification of the drugs, its duration and 
administration 
2. Clinical imaging and histopathological patterns which are consistent with earlier 
observations of the same drug 
3. Exclusion of other lung disease 
4. Improvement after discontinuation of drug suspected 
5. Recurrence of symptoms on rechallenge  
 In our case series the diagnosis was made at the discretion of different clinicians and once other causative 
causes such as infection were excluded.  
We aimed to describe series of IBD patients with a diagnosis of ILD or GLD and try to elicit 





2.1 Study design 
This observational multicentre study retrospectively collected cases across the world through 
the CONFER (COllaborative Network For Exceptionally Rare case reports) project9 and supported by 
the European Crohn’s and Colitis Organisation (ECCO) . The CONFER project was initiated by ECCO 
in order to specifically identify and report rare IBD disease associations, which are otherwise seldom 
reported due to their exceptional rarity. Briefly, the CONFER methodology comprised selecting a topic 
worthy of investigation out of case proposals submitted by ECCO members. The steering committee of 
CONFER chose the topic, and ECCO launched a call to identify similar cases encountered by IBD 
physicians worldwide.  
The call to physicians was made through announcements in the ECCO annual congress and in 
national IBD meetings across Europe and during several international IBD meetings. In addition, the call 
for similar cases was disseminated by direct emails to all ECCO members and affiliated physicians, and 
on the ECCO website and in the ECCO eNews. Physicians were then prompted to report their cases to 
the CONFER database using a pre-determined standardized case report form. The call for the present 
case series was entitled Interstitial and granulomatous lung disease in IBD. 
2.2 Patients and procedures 
All adult IBD patients (age >16 years) with a GLD or ILD diagnosis, according to established 
classifications6,7 throughout the course of IBD or prior to its diagnosis were eligible for inclusion in this 
study. GLD and ILD diagnosis was made based on clinical presentation according to prior case reports 
and reviews. Relationship between IBD treatment and pulmonary disease was established by the 
physician, based on the patients’ medical history and relevant tests, when applicable. Data were collected 
using a case report form, which was divided into five domains. Section 1 included patient 
(epidemiological data, past medical history, smoking habits, previous lung disease) and disease 
characteristics. Section 2 was focused on event description, Section 3 on event presentation and 
investigations, Section 4 on treatment and section 5 on respiratory and IBD outcomes. All the 
participating centres reviewed patient charts and enrolled all the patients eligible.  The data were 
collected and analysed anonymously and handled according to local regulations. All the adverse events 
discussed in the text and related to any drug have been reported to the Pharmacovigilance according to 
the local regulations.   
2.3 Statistics 
For the statistical analysis, IBM Software SPSS Statistics Version 22.0.0 (2013 SPSS Science, 
Inc., Chicago, IL) was used. Depending on the number and the distribution of the data, appropriate tests 




3.1 Interstitial lung disease patients 
A total of 31 patients with ILD were identified from 14 medical centres. Patients’ characteristics 
are shown in Table 2. All patients had a diagnosis of IBD prior to ILD with a median time of 10.3 years 
(range 0.3-51 years). Eight (25.8%) patients had IBD disease activity at the time of ILD diagnosis.  
Eleven (35.5%) patients had non drug related ILD and 20 (64.5%) had drug related ILD (mesalazine 
n=9, methotrexate n=1, golimumab n=1, vedolizumab n=1 and infliximab (IFX) n=8). One patient had 
2 different drugs induced ILD related to vedolizumab and golimumab and each event was analysed 
separately. Main characteristics and outcomes of reported ILD are shown in Figure 1.  
3.1.1 Non drug related data 
Eleven patients were identified, 10 (90.9%) male, with mean age at event 51.6 years (range 20-
67 years). Mean duration of IBD was 13.3 years (range 1.3-51 years) at the time of the event. Eight 
(72.7%) patients had previous lung disease (asthma n=1, previous Pneumocystis jirovecii (PJ) 
pneumonia n=1, pulmonary embolus n=1, previous p ANCA n=1, not specified n=4) (Table 2). The main 
reported symptoms were cough (n=10, 90.9%), shortness of breath SOB (n=9, 81.8%), fever (n=2, 
18.1%) and lethargy (n=3, 27.2%) with duration of symptoms varying from 12 days to 1 year. 
Investigations showed that 8 patients (72.2%) had abnormal Chest X-ray (CXR), two had 
positive autoantibodies (1 ANA positive and 1 ANCA positive). All had abnormal chest high resolution 
computerized tomography (HRCT).  Bronchoscopy was done in seven patients (63.6%) (abnormal n=3, 
normal n=4). Only 6 patients (54.5%) underwent lung biopsy (Table 2). Diagnoses of ILD included 
Cryptogenic Organizing Pneumonia (COP) in five patients (45.4%), idiopathic fibrosis in 3 (27.3%), 3 
(27.3%) unclassified. Nine patients (81.8%) were hospitalized and seven (63.6%) received steroids and 
4 of those for long term.  One of the patients required non-invasive ventilation with BIPAP duration on 
1 month.  
At mean follow up of 10 months  (ranging from 4 months to 9 years) 3 (27.3%) had ongoing 
symptoms, 5 (45.4%) had complete resolution of symptoms and 1 had ongoing symptoms despite long 
term steroids and was then given methotrexate and referred for consideration of lung transplantation, 
whereas data were missing for 2 patients.  On review, 2 (18.2%) had abnormal CXR, 5 (45.4%), 3 
(27.3%) had abnormal HRCT. Eight patients (72.7%) had active IBD, two (18.2%) quiescent and three 
(27.3%) had a flare. Out of those who had a flare one was started on adalimumab, one on IFX and one 
on tacrolimus. One of the patients underwent proctocolectomy for colonic dysplasia. ILD characteristics 
and outcome are also summarized in Supplementary Table 1.  
 3.1.2 ILD: Drug related data 
 A total of twenty cases were identified (mesalazine n=9, methotrexate n=1, golimumab n=1, 
vedolizumab n=1 and IFX n=8). Patients’ epidemiological and IBD characteristics are summarized in 
Supplementary Table 2 and 3.  
3.1.2.2. Biologics 
Anti TNF 
 Infliximab (IFX) 
There were 8 cases (40% of drug related cases) with IFX induced interstitial lung disease. 
Patients were on IFX (5mg/kg) with a mean duration of 5.4 doses (range 2-8 doses). Main symptoms 
were: cough (n=6, 75%), SOB (n=8 100%), fever (n=3 37.5%) and lethargy (n=4 50%) with a mean 
duration of symptoms of 6.3 weeks (1 day-24 weeks). All patients had negative virology and bacterial 
screen. Five (62.5%) had abnormal CXR and six (75%) all of them had abnormal HRCT and only 1 had 
abnormal bronchoscopy.  Only 3 (37.5%) had lung biopsy done.  
Diagnosis included 3 with COP (37.5%), 2 with idiopathic fibrosis (25%) and 3 (37.5%) with 
unclassified interstitial lung disease. Five patients (62.5%) were admitted and IFX was stopped in all 
patients. Once infection was excluded, six patients received steroids (75%) for duration between 1-6 
months.   
At mean follow up of 4.6 months (ranging from 1-14 months), 5 (62.5%) patients had ongoing 
symptoms. Five (62.5%) had normal CXR, 1 (12.5%) still had ongoing abnormalities. CT was normal in 
1 patient (12%), but the majority (6) had ongoing abnormalities (75%). Three of these patients showed 
improvement. With regards to IBD, 4 had active disease at follow up (50%), 3 had quiescent disease 
(37.5%). Two required steroids to control their disease and 5 had new medications initiated (5ASA n=1, 
AZA n=1. adalimumab n=1, vedolizumab n=1, ustekinumab n=1).  
 Golimumab 
There was only one case of female patient (5% of drug related cases) with UC E3 undergoing 
golimumab and vedolizumab. Clinical characteristics are included Supplementary Table 2. There was 
previous use of IFX and vedolizumab and previous lung disease due to vedolizumab with acute 
interstitial pneumonia.  She presented at age 24 after 2 doses of golimumab and active IBD at event. 
Symptoms included cough, SOB, fever and lethargy. She had abnormal CXR and HRCT.  Diagnosed as 
cryptogenic organizing pneumonia and admitted to hospital and treated with steroids for 1 month. 
Despite treatment, she had ongoing active IBD that required steroids and was readmitted and had surgery 
subtotal colectomy and ileostomy. 
Vedolizumab 
The same patient (as above) previously developed ILD (Unclassified) disease duration at event 
was 12 years and age at presentation was 24 years. Lung disease presented with SOB after 2 doses of 
vedolizumab with: cough, SOB, fever, lethargy. She had abnormal CXR, HRCT, and bronchoscopy.  She 
was diagnosed with and treated with steroids and was admitted to hospital. Had ongoing active IBD at 
review 4 months later and was admitted with a flare that required steroids and started Golimumab. 
3.1.2.3 5 ASA 
There were 9 patients (45% of drug related cases), 6 of them male (66.7%). Two (22.2%) 
patients had previous lung disease (asthma n=1, Sjogren’s syndrome n=1). Patients’ ILD characteristics 
and outcomes are summarized in Supplementary Table 3. Mean age at time of event was 52 years 
(ranging from 19-80 years) with mean duration of IBD 6.6 years ( ranging from 0.8-14 years). At the 
time of event two (22.2%) patients had active disease, and seven (77.8%) had quiescent.  
5-ASA means dose at event was 2.3 g (range 0.8-3 g) and means duration of 5-ASA use was 
5.11 years (range 0.8-14 years). Presenting symptoms were: cough (n=7), SOB (n=8), fever (n=6), 
lethargy (n=1) with mean duration of 7.5 weeks (ranging from 1.5-12 weeks). All patients had abnormal 
CXR and CT. One had abnormal bronchoscopy (11.1%) and only two had lung biopsy (22.2%). 
Diagnosis included 2 patients with COP (22.2%) 5 had ILD unclassified (55.5%), 1 with idiopathic 
interstitial disease (3.3%) and 1 with eosinophilic pneumonia (3.3%). The drug was stopped in all 
patients. Eight (88.9%) patients were admitted to hospital, and treated with steroids (88.9%) with mean 
duration of 6.47 months (0.3-24 months). 2 with long term use. Any infection was excluded prior to 
commencing steroids.  
At  mean follow up of 11.6  months, (ranging from  3-24), 5 patients (55.5%) had ongoing 
symptoms, 4 had abnormal CXR (44.4%), 2 (50%) had improvement. Three (33.3%) had abnormal 
HRCT.  One (11%) became steroid dependent and died 5 years later due to progressive lung disease. 
After treatment, 1 patient (11%) had a flare that required steroids, 3 (33.3%) started new medications 
(AZA, steroids 1 restarted 5-ASA). 5-ASA induced ILD characteristics and outcome are also 
summarized in Supplementary Table 3. 
3.1.2.4 Methotrexate 
Only 1 patient (5%) was identified, a female with CD L2. Age at event was 44 years old and at 
presentation was on MTX for 2 years with 15 mg every week and her IBD was in remission.  Presented 
with cough, SOB, fever and lethargy that lasted few days. Abnormal CXR and spirometry (mixed 
restrictive and obstructive pattern) and also abnormal HRCT were reported. She was treated with steroids 
for 1 month after being admitted to hospital. A diagnosis of ILD (Unclassified) was made. At review 1 
month later she had lethargy, normal CXR. Subsequently, she had a flare of her CD and adalimumab 
was started 3 years later. 
3.2 Granulomatous lung disease patients 
We identified 22 GLD patients from 18 university hospitals, most of them with CD (77.3%). 
Patients’ characteristics are shown in Table 2. In 17 patients, IBD diagnosis preceded lung disease 
diagnosis in a median time of 10.6 years (range 0.5-27 years); only 4 patients had active disease at the 
time of GLD diagnosis. In 4 patients, lung disease was diagnosed in a median time of 14 months (range 
8-24 months) before IBD and in 1 patient IBD and lung disease diagnoses were established 
simultaneously. 
A total of 14 cases (63.6%) were considered non drug related GL (primary sarcoidosis n=7, 
fungal infection n=2 and unspecified n=5) and 8 cases (36.4%) were considered drug-related GLD  (IFX 
n=4, certolizumab n=1, adalimumab n=1, vedolizumab n=1 and azathioprine (AZA) n=1) out of which 
5 had sarcoidosis. Characteristics of GLD and outcomes are shown in Figure 2. 
3.2.1 Non drug related GLD 
We identified 14 patients (63.6%) with non-drug related GLD and IBD, 11 male (78.6%), with 
mean age at event of 44.5 years (range 18-85 years). At event only 4 patients had active IBD disease.  
Nine patients presented with cough (64.3%), 4 with SOB (28.6%), 2 with fever (14.3%) and 2 with 
weight loss (14.3%). Investigations showed that 12 patients had abnormal CT scan (85.7%), 11 (78.6%) 
had abnormal CXR, 4 had abnormal spirometry (28.6%, restrictive pattern n=2, obstructive pattern n=2).  
Three had abnormal bronchoscopy and 12 patients (85.7%) had a lung biopsy compatible with 
granulomatous non-necrotizing disease.  
Diagnosis was primary sarcoidosis in seven patients (50%) (6 males; 4 patients with CD and 3 with UC). 
1 patient was under anti-TNF therapy (adalimumab), 1 was under immunosuppressive therapy (AZA), 2 
under 5-ASA therapy and 3 without therapy. The first patient was under adalimumab therapy for just 
only 1 month when the diagnosis of sarcoidosis was established. Due to progressive deterioration with 
weight loss, fatigue and arthralgia, further investigation was made which revealed systemic 
granulomatosis with skin, lung, spleen, bone, heart, bone marrow, joint (right knee) and gastro-intestinal 
involvement. Due to severe lung deterioration and cardiac involvement, a high dose of steroids was 
initiated.  
In the remaining 6 patients both diagnosis of IBD (CD n=3, UC=3) and sarcoidosis were made: 
initially all patients received steroids and during the follow up 2 patients started on immunosuppression 
with AZA achieving remission of both conditions, whereas 1 UC patient, who had already been 
submitted to proctocolectomy, was started on immunosuppression with MTX due to ongoing respiratory 
symptoms.  
Five patients (36%) were considered to have an unspecified GLD (3 males; all of them with 
CD): 2 patients had no IBD medication (lung disease was established before or at the same time as IBD), 
2 patients were under 5-ASA and 1 under MTX. All patients initially received steroids. Additionally, 
during the follow up, 4 patients started anti-TNF therapy (adalimumab), of whom 3 achieved steroid-
free remission of both conditions. 
We identified 2 patients (14%) (2 males; 1 patient with CD and 1 with UC) with a GLD caused 
by a fungal infection: 1 patient was under systemic steroid therapy and 1 patient had the diagnosis of 
pulmonary histoplasmosis made before IBD diagnosis. At follow up, both patients had no ongoing 
pulmonary symptoms. With regards to IBD, the first patient had pancolitis and during the follow up was 
submitted to surgery (IPAA) to control IBD and the other still had disease activity despite the 
introduction of budesonide therapy.  
Among patients with non-drug related GLD hospital admission was needed in 8 patients 
(57.1%) but none needed invasive ventilation. Remission of both conditions was achieved in almost all 
patients.  
3.2.2 Drug related GLD  
We identified 8 patients (36.4%) with drug related GLD (IFX n=4, certolizumab n=1, 
adalimumab n=1, vedolizumab n=1 and AZA n=1) and IBD, 6 males (75.0%), with mean age at event 
48.1 years (35-76 years). At event presentation only 1 patient had active IBD disease. Six patients 
presented with cough (75.0%), 5 with SOB 62.5%), 5 with lethargy (62.5%), 3 with fever (37.5%) and 
2 with weight loss (25.0%). Investigations showed that all patients had abnormal thorax CT scan and 3 
had abnormal spirometry (37.5%, restrictive pattern n=2, mixed pattern n=1). Bronchoscopy was done 
in 7 patients (abnormal n=2, normal n=5). Most of patients (n=5, 62.5%) had lung biopsy, all of them 
compatible with granulomatous non-necrotizing disease 
3.2.2.1 Biologics 
Anti-TNF  
There was a total of 6 cases (75.0% of drug related cases) with anti-TNF induced GLD. 
Diagnosis included 5 patients with sarcoidosis (83.3%) and one with GLD unspecified (16.7%). In the 
sarcoidosis group (n=5)  (3 males, 4 with CD), mean age of 41.4 years: all of them were under anti-TNF 
therapy (IFX n=3, adalimumab n=1, certolizumab n=1) for a mean time of 55 months (range 10-108). 
Causative drug was stopped in all patients and 2 also received steroids. At mean follow up of 33 months 
(range 12-84 months) there were no patients with ongoing respiratory or IBD symptoms.  3 patients were 
started on vedolizumab therapy and 1 patient treated with IFX was successfully switched to adalimumab 
(data not available for 1 patient). In 1 male patient with CD who was on IFX for 72 months he had 
diagnosis of GLD (non-sarcoidosis) related to anti-TNF. The anti-TNF was stopped and was given 
steroids with resolution of respiratory symptoms. When reviewed at 3 months and AZA was started for 
maintenance of his IBD. The patient also received steroids with resolution of respiratory symptoms.  
Vedolizumab 
There was only one case of a male patient with CD (12.5% of drug related cases). This patient 
had the diagnosis of CD established 7 years before and had already been treated with AZA and 
golimumab. After 4 months of vedolizumab therapy (300mg q4w) he developed cough, SOB and 
lethargy. He had a diagnosis of GLD secondary to vedolizumab. Vedolizumab was stopped and he was 
treated with steroids with resolution of respiratory symptoms. Due to active IBD, 15 months later he was 
started on anti-TNF therapy.  
3.2.2.2 Azathioprine (AZA):  
There was only one case of male patient with CD (12.5% of drug related cases). This patient 
had the diagnosis of CD established 7 years before and was in remission under AZA (2.5mg/Kg). After 
24 months of AZA he developed cough, SOB and lethargy and it was established the diagnosis of 
unspecified GLD.  The patient was admitted, AZA was stopped and he was treated with steroids. Four 
years later the patient still needed steroids (10mg/day) to control respiratory symptoms and still had 
abnormal CT chest and spirometry. There was no need for new IBD therapy.   
  
Among patients with drug related GLD hospital admission was needed in 2 patients (25%) but 
none needed invasive ventilation. Remission of both conditions was achieved in all patients, with only 1 
patient still needed steroid to control lung disease 
  
4. Discussion 
Even though pulmonary manifestations in IBD are rare they are increasingly recognised10,11. 
The true prevalence in IBD remains unknown12,13. Our retrospective study describes a series of IBD 
patients affected by ILD (n=31) and GL (n=22).  Most of cases were reported to be drug related (n=28) 
and 25 were non drug related cases. Most of the current data in literature comes from rheumatological 
patients and also small case series and our study provides insight into the IBD population. 
Establishing an accurate diagnosis of ILD can be challenging for clinicians as there are more 
than 200 different subtypes and over the past decade ILD has been reclassified in comprehensive 
international consensus statements6,7.  Determination of disease subtypes requires consideration of 
patients’ clinical features, radiological pattern, and serology and in some cases lung biopsy.14 15-21.  
Granulomatous lung disease diagnosis can also be challenging to diagnose. Even with histology 
it can be difficult to distinguish between sarcoidosis and Crohn’s disease. In fact, both entities are barrier 
disorders of unknown aetiology, with several aspects in common (non-necrotizing granulomas, an 
increased intestinal permeability, local and peripheral T-cell activation and an increased 
proinflammatory cytokine release)22-27. Moreover, the patterns of possible organ involvement outside the 
primary manifestations in the lung and gut are similar and include eye, skin, joints and liver. Sarcoidosis 
manifestations in the gut, CD manifestations in the lung and manifestations of both diseases in the same 
patient have been reported in rare cases, which may impose considerable diagnostic difficulties22-27. 
In our case series, 11 patients had non drug induced ILD with male predominance and 73% with 
pre-existing lung disease and concomitant UC. None of the pre-existing lung disease included previous 
ILD.  Only 6 patients had lung biopsy making classification difficult with 3 cases unclassified.  Three 
cases were diagnosed as IPF which is a progressive lung disease two of which had ongoing respiratory 
symptoms and radiological changes but one no respiratory data exist. One of the ILD unclassified cases 
had progressive deterioration of his respiratory symptoms requiring referral for consideration of lung 
transplantation despite ongoing steroid treatment.  A high proportion of were admitted and treated with 
steroids with resolution of symptoms in 45% of patients, which possibly is related to the ILD subtype of 
COP, which has a good prognosis and responds to steroid treatment. 
We also identified 14 patients with non-drug related GLD and 12 patients had lung biopsy. 
Diagnosis was 7 patients with sarcoidosis and 5 had GLD unclassified which again demonstrates the 
difficulty in diagnosis, 2 cases were due to fungal infection. Almost all cases recovered with the use of 
steroids and AZA (sarcoidosis) or IFX (unspecified GLD).   
The most common pulmonary manifestations of IBD are drug-induced lung disease. Most of 
IBD drugs have been implicated and definitive diagnosis of drug induced lung disease can be difficult. 
Clinical presentation and exclusion of other causes play important role in making the diagnosis, but 
sometimes invasive procedures such as bronchoscopy and lung biopsy might be necessary22-27.   
 Patients can present with virtually all histopathological patterns of either ILD or GLD.  Moreover some 
drugs can produce more than one pattern of respiratory involvement.  There have been some risk factors 
for developing drug related lung disease include: extremes of age, sex, ethnicity, dose of medication, 
oxygen, drug interaction and underlying lung disease28. Diagnostic criteria exist as mentioned earlier but 
despite that it can still be a difficult diagnosis8. 
 
Sulfasalazine and mesalazine, side effects are rare and can be dose related or idiosyncratic. 
Mesalazine induced lung injury is rare and usually presents as interstitial and eosinophilic pneumonitis, 
bronchiolitis obliterans and eosinophilic pleural effusion29. Case report data suggest mesalazine induced 
lung toxicity follows a milder course, however, there have been case reports with more severe 
presentation requiring intubation30. A recent review of 50 cases of sulphasalazine lung toxicity most 
patients presented with cough, breathlessness, fever and weight loss. Most of cases presented with 
chronic interstitial pneumonias, desquamative interstitial pneumonitis, eosinophilic pneumonitis and 
acute interstitial pneumonia. Clinical improvement occurred in majority of cases with resolution 
occurring with average for 6 1/2 weeks after initiation of therapy. There were 5 deaths due to pulmonary 
pathology and all cases had UC as underlying condition31. In another review of case reports of 5-ASA 
induced lung toxicity, mean age of presentation was 46 years with most cases being female and having 
UC as underlying disease. The time for appearance of symptoms ranged from 2 days to 8 years32. 5-ASA 
lung toxicity usually responds to discontinuation of drug and some may require a course of steroids33. In 
our case series we identified 9 cases and unlike the literature most of them were male (67%) and 89% 
had ulcerative colitis. The mean duration use of 5ASA was 5.1 years (range 0.8-14 years) which is similar 
to the previous review.  Only 2 patients had lung biopsy and most cases were ILD unclassified. At follow 
up 55% of them had ongoing respiratory symptoms. There was 1 death due to progressive fibrosis. This 
was an 81 year-old male patient that was diagnosed with idiopathic pulmonary fibrosis and became 
steroid dependent.  
The use of anti-TNF drugs (IFX, adalimumab, golimumab, certolizumab) in IBD has increased 
and improved the outcomes of IBD patients34,35. The most important side effects include increased risk 
of opportunistic infections36. There has been some evidence that anti-TNF therapy can cause acute 
respiratory distress syndrome, diffuse alveolar haemorrhage37 and ILD38-41. A large scale post-marketing 
surveillance study in Japan on safety of IFX in rheumatology patients revealed that the development of 
ILD was a rare event of 0.5% (25/5000). Mean age of those patients was 62.9 years and pneumonitis 
occurred after a mean dose of 2.8 infusions of IFX42. Another case control study from Nakashita 
investigated the potential risk of TNF inhibitors on progression of ILD in patients with RA revealed 
increased risk of ILD events and also progression of pre-existing ILD disease43. Patients presented mostly 
with dyspnoea and cough with IFX use of 6-14 weeks prior to presentation. Diagnosis included: 
nonspecific interstitial pneumonitis, drug related alveolitis, drug induced interstitial lymphocytic 
pneumonitis; all had discontinuation of IFX with complete resolution of symptoms with steroids44-46. 
There has been one case report of fatal acute interstitial pneumonia after accelerated dose of IFX for 
acute severe UC47. In our case series we identified 8 IFX induced ILD cases with male predominance.  
Only 2 patients had lung biopsy. One young male was diagnosed with idiopathic pulmonary fibrosis but 
he responded to steroids and therefore unclear whether that diagnosis was the correct one. Most of our 
patients had ongoing symptoms and radiological changes despite steroid treatment and discontinuation 
of the drug. The different outcome might be due to the diversity of the subtype of ILD as different 
subtypes have different outcomes. 
 
Another uncommon pulmonary adverse event associated with anti-TNF therapy is the 
development of sarcoid like lesions. The estimated frequency is 1:28000 (0.04%) which comes from  
case reports published from rheumatological data48,49,50. Symptoms are nonspecific, including dyspnoea, 
non-productive cough, erythema nodosum, parotid enlargement, and neuro-ocular manifestations. 
Radiologically, the most common findings are mediastinal and hilar adenopathy, and less frequently, 
upper lobe opacities. The diagnosis is confirmed histologically by the presence of well-formed non-
necrotizing granulomas. Ultimately, sarcoidosis is a diagnosis of exclusion, once all infectious causes 
have been ruled out51.  In a recent review of the available literature, the authors evaluated the published 
cases of sarcoidosis associated with anti-TNF therapy and found a total of 90 patients with median age 
of 43 years (7–72) and a female predominance (61%). The underlying anti-TNF therapy was etanercept 
(n=53, 59%), adalimumab (n=21, 23%) and IFX (n=16, 18%) and the median duration between initiation 
of anti-TNF therapy and diagnosis was 22.5 months (1–84). Regarding treatment options, in 43 cases, 
the anti-TNF therapy was discontinued and steroids were started, with an improvement or resolution in 
41 cases (95%), in 37 cases, anti-TNF discontinuation was the only intervention, giving improvement in 
32 cases (86%), in 5 cases, addition of steroid therapy alone gave improvement in 4 cases (80%), in 1 
out of 3 cases improvement was observed without any intervention (33%). In 20 cases, the anti-TNF was 
restarted therapy: in 6 cases the same drug was used, which gave recurrence in 4, and in 14 cases, another 
anti-TNF was initiated with relapse in 352. In our series we found a male predominance but the other 
characteristics and outcomes are similar to those previously reported. All patients fully recovered by 
stopping anti-TNF therapy and receiving steroids.   
No data exists on IBD population regarding golimumab induced ILD. According to the EMA 
2009 Assessment report, serious non-infectious pulmonary adverse events were observed in five Phase 
3 trials of golimumab for the treatment of rheumatoid arthritis, ankylosing spondylitis or psoriatic 
arthritis: 1 case of interstitial disease, 2 of pneumonitis and 1 of fibrosing alveolitis53-58. Most of patients 
were also on methotrexate and therefore unable to make a definite association between ILD and 
golimumab. We reported a case of a young woman with previous use of IFX and previous lung disease 
due to vedolizumab who had golimumab induced COP and required steroids.  Unfortunately, no 
respiratory follow up data was available but ended up having subtotal colectomy and ileostomy for UC 
after 2 months following further flare after stopping golimumab.  
Vedolizumab, unlike other drugs used for IBD, has not been associated with the development 
of serious opportunistic infections and malignancies59. However, clinical observations indicate an 
increased risk for extra-intestinal autoimmune events under this therapy60. There have been 2 case reports 
of ILD in the literature61,62 . The only case of vedolizumab related ILD (Unclassified subtype) reported 
in our cohort responded to steroids but had further admissions due to flare of her disease and required 
golimumab therapy.  
We also reported a case of a CD male patient who developed cough, shortness of breath and 
lethargy 4 months after starting vedolizumab. He was diagnosed as GLD associated with vedolizumab 
therapy, but, as the similar case recently published63, this patient can be re-classified as a patient with 
newly developed pulmonary manifestation of CD under vedolizumab. 
MTX may be useful in IBD treatment but can cause adverse events in lungs that can be lethal64. 
The mechanism is unclear and thought to be an idiosyncratic reaction that can cause interstitial 
pneumonitis and bronchiolitis65. MTX pneumonitis is a rare complication with only 123 case reports in 
the literature. Most of cases have a subacute onset and it is most common within the first year of 
treatment, with a reported incidence that varies from 0.8 to 6.9%66,67. Treatment of MTX pneumonitis 
includes withdrawal of MTX, high dose corticosteroids and supportive therapy67. We identified 1 case 
that presented with ILD unclassified after 2 years of weekly MTX use due to CD who was treated with 
1 month of steroids with resolution of symptoms. 
Pulmonary toxicity due to AZA/6-MP has been reported infrequently in the literature, although 
interstitial pneumonitis, restrictive lung disease, Goodpasture-like syndrome and pulmonary 
haemorrhage have been described after use of these drugs12. The largest series of lung toxicity related to 
AZA with description of 7 cases on AZA therapy was reported in patients undergoing renal allograft 
transplantation immunosuppression. Lung biopsies revealed interstitial pneumonitis in 5 patients and 
diffuse alveolar damage in 2 patients; 3 patients died and the other 4 improved after stopping AZA and 
in 2 of these patients cyclophosphamide therapy to resolve completely this side effect was needed69. 
There are no cases of GLD due to AZA / 6-MP in the literature. Here we described a case of a CD male 
patient in remission who developed cough, shortness of breath and lethargy 24 months after AZA 
initiation. He was diagnosed with AZA related GLD and was admitted and responded to steroids and 
became steroid depended to control his respiratory symptoms, with ongoing radiological and spirometry 
changes 4 years later. 
Our study has several limitations: it was a retrospective case report data collection and it relied 
on voluntary submission of cases by physicians who responded to the ECCO calls and therefore might 
be subject to geographical and selection biases. Only 12 ILD cases (38.7%) had lung biopsy and 17 GLD 
cases (77%) which resulted in a lot of cases having ILD Unclassified. The classification of ILD and 
whether a drug was the caveat was depended on the clinician submitting the relevant info and as cases 
were collected from 2000-2017 the classification might have not been the correct one as classification of 
ILD has been revised 2013-2015. 
 Due to the low sample size the correlation between IBD therapies and lung disease is challenging to 
assess.  Also no risk factors or predictors can be investigated due to the very low sample size, and the 
heterogeneity of cases. 
Conclusion 
ILD and GLD although rare can cause significant morbidity. About half of our cases were drug 
related and therefore clinicians should be more vigilant regarding IBD medications especially when 
infectious causes have been excluded. Early recognition and treatment is important as most respond to 
withdrawal of medication and use of steroids. 
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Table 1: Classification of pulmonary abnormalities in association with IBD (non-drug 
related) 
1. Upper Airways 
o Epiglottitis 
o Tracheobronchitis 
2. Large airways  
o Bronchiectasis 
o Acute or chronic bronchitis 
3. Small airways  
o Bronchiolitis 
o Bronchiolitis obliterans 
4. Interstitial disease:   
o Non-specific interstitial pneumonia 
o Acute interstitial pneumonia  
o Cryptogenic organizing pneumonia 
5. Autoimmune disease:  
o Wegener’s Granulomatosis  
o Pulmonary vasculitis 
o Churg Strauss syndrome 
6. Vascular disease 
o Pulmonary embolism 
7. Other pulmonary manifestations 
o Necrobiotic nodules 
o Pleuritis  






Table 2.  Clinical characteristics of inflammatory bowel disease patients  
 Patients with GLD (n=22) Patients with ILD (n=31) 
Age (years) 46.4 (18-86) 47 (17-84) 
Sex 
17 (77.3%) males : 5 (22.7%) 
females 
19 (61.3%) males : 12 (38.7%) 
females 
Age at diagnosis (years) 32.2 (10-74) 49.65 (17-84) 
CD / UC /  indeterminate 
colitis 
17 (77.3%) / 5 (22.7%) / 0 8 / 22 / 1 
Montreal classification   
A1 / A2 / A3 1 / 10 / 6 2 / 5 / 3 
L1 / L2 / L3 4 / 8 / 5 0 / 7 / 3 
B2 / B2 / B3 11 / 5 / 0 7 / 2 / 1 
E1 / E2 / E3 0/ 2 / 3 0 / 6 / 17 
Perianal disease 5 (22.7%) 4 (12.9%) 
Extra-intestinal 
manifestations 
8 (36.4%) 11 (35.5%) 
Positive family history of 
IBD 
3 (13.6%) 4 (12.9%) 
Previous lung disease 3 (13.6%) 11 (35.5%) 
Smoking: 
current/past/never 
3 (13.6%) / 7 (31.8%) / 12 
(54.5%) 
0 /10 (32.3%) / 21 (67.7%) 
IBD Activity at event: 
active / quiescent 
4 (18.2%) / 18 (81.8%) 11 (35.5%) / 20 (64.5%) 
Drug related lung disease 8 (36.4%) 20 (64.5%) 
5-ASA / MTX / 
AZA / anti-TNF / 
VEDO 
0/ 0/ 1 / 6 / 1 9 / 1 / 0/ 9 / 1 
Legend: 5-ASA (5-aminosalicylic acid); MTX (methotrexate); AZA (azathioprine); anti-TNF 
(anti-tumour necrosis factor); VEDO (vedolizumab) 
 







IBD Symptoms CXR CT Bronchoscopy Biopsy 
Diagnosi
s Steroids IBD outcome 
1 21, F 5ASA 48 months C,SOB,T,L Multifocal 





and R pleural effusion 
Extrinsic 
compression at R 
lobe due to 
Effusion 






2 64,M ADA 40mg 
weekly 
51 years C, SOB opacities Bronchial wall 
thickening, opacities 




















COP Yes, 60 mg for 






4 20,M Vedolizumab 
300mg 8 
weekly 




NA NA COP No Quiescent 
5 67,M Nil NA C Interstitial lung 
pattern 
Tree in bud pattern in 
R lobe 
Normal Not done ILD 
Unclassif
ied 
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10 70,M 5ASA, AZA, 
Steroids 
16 Months SOB NA Septal thickening and 
reticular changes in 
upper lobes, 
honeycomb 














IPF Yes, 60mg NA 
C=cough, SOB=Shortness of breath, T=Fever, L=lethargy       
COP= Cryptogenic organizing pneumonia, IPF= Idiopathic pulmonary fibrosis, ILD =Interstitial 
lung disease 
      
      
  









infliximab Symptoms CXR CT Bronchoscopy Biopsy Diagnosis Steroids IBD outcome 
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for 20 days 
with 
inhalers Quiescent 
3 16,M Nil 7 doses C,SOB,L Normal 
Diffuse 
bronchiectasis 
R middle lobe 






































Flare of disease 
started 
Ustekinumab 














alveoli COP Yes, 20mg 















Focal ground glass 
opacities R upper 
lobe and bilateral 
lower lobe diffuse 
ground glass 
opacities  Normal Not done 
ILD 
unclassified No Quiescent 
8 48,M 5ASA, AZA 
5 doses last 
one 2 months 














































areas of organizing 
pneumonia  Normal Not Done COP 


























































Vedolizumab Symptoms CXR CT 
Broncho
scopy Biopsy Diagnosis Steroids IBD outcome 












changes ILD Unclassified 





            
            
  









dosage Symptoms CXR CT Bronchoscopy Biopsy Diagnosis Steroids IBD outcome 
1 66, F 
Previous AZA 















granulomas  COP Yes months  
One flare treated 
with steroids 
2 26, F 
Budesonide, 











effusions NA Not done ILD Unclassified Pt refused Restarted 5ASA 
3 18, M Nil 3gr 10 months C 
Shadows 
in apex 



















term   










pneumonia Normal Not done COP 
Yes, 20mg 
for 1 month 
Pt started on IFX 
5 years later 





infiltrates Normal Not done ILD Unclassified 
Yes 50mg for 
3 months Quiescent 









appearance Normal Not done COP 
Yes 50mg for 
3 months Quiescent 







and areas of 
ground 
glass Normal Not done ILD Unclassified 
Yes 40mg for 
2 months Quiescent 







infiltrates Normal Not done 
Eosinophilic 
Pneumonia 
50mg for 10 
days  














lobes NA NA IPF 
yes 30mg 
tapered 
slowly 10mg  
long term 
Death due to 
pulmonary 
fibrosis 
            












ds IBD outcome 
1 44,F 
Nil, previous 
IFX and aza 
MTX 25mg for 2 
years C, SOB, T, L 
Bilateral reticular 















            
 
Figure Legends 
Figure 1: Characteristics and  respiratory outcomes of ILD related to IBD (non- and drug-related) in our cohort. 
Figure 2: Characteristics and  respiratory outcomes of GLD related to IBD (non- and drug-related) in our cohort. 
 
